October 20, 2016 P&T Committee Agenda

Page 2

Virginia’s Department of Medical Assistance Services

Pharmacy and Therapeutics Committee Meeting

600 East Broad Street – 7th Floor Conference Rooms

Richmond, Virginia 23219

Thursday, October 20, 2016 - 10:00 a.m.

Welcome and Comments from DMAS’ Director / Cynthia B. Jones
Comments from DMAS’ Chief Medical Officer / Kate Neuhausen, MD, MPH
Call to Order / Tim Jennings, PharmD, Chairman
Drug Utilization Review (DUR) Board Update / Avtar Dhillon, MD, DMAS DUR Board
Approval of Minutes From April 28, 2016 Meeting / P&T Committee Members
PDL Management / P&T Committee Members

·  PDL Phase II – Long Acting Opioids Review

·  PDL Phase II – New Drug Review

o  Acne Agents (clindamycin/tretinoin - generic for Veltin®)

o  Antifungals, Topical (oxiconazole - generic for Oxistat®)

o  Antivirals Hepatitis C (Epclusa® & Viekira XR™)

o  Antimigraine Agents, Triptans (Onzetra™, Xsail™, Zembrace™, SymTouch™, frovatriptan, Migranow® Kit)

o  Cytokine & Cam Antagonists (Taltz®)

o  Diabetes Hypoglycemics Alpha-Glucosidase Inhibitors (miglitol - generic for Glyset®)

o  Diabetes Hypoglycemics Incretin Mimetics/Enhancers (Jentadueto XR®, alogliptin - generic for Nesina®, alogliptin/metformin - generic for Kazano®, alogliptin/pioglitazone - generic for Oseni®)

o  Multiple Sclerosis (Zinbryta™)

o  Nonsteroidal Anti-Inflammatory Drugs (diclofenac 1% gel - generic for Voltaren®, Xrylix® Kit, Vopac® MDS)

o  Otic Antibiotics (Otovel)

o  Stimulants and Related Agents (Adzenys XR ODT™ & armodafinil - generic for Nuvigil®)

·  PDL Phase I – Annual Review

Antibiotic-Anti-Infective

·  Antibiotics, Vaginal

Blood Modifiers

·  Bile Salts

·  Phosphate Binders

Cardiac Medications

·  Angiotensin Modulators (ACEs, ARBs, & combination products)

·  Angiotensin Modulators II (Direct Renin Inhibitors & combination products)

·  Antihypertensives, Sympatholytics

·  Beta Blockers (includes combination products)

·  Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)

·  Lipotropics, Others (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)

·  Lipotropics, Statins

·  Pulmonary Hypertension Agents (Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilators, Soluble Guanylate Cyclase Stimulators)

Central Nervous System

·  Alzheimer's Agents

·  Anticonvulsants

·  Antidepressants

·  Antidepressants, SSRI

·  Antipsychotics

·  Sedative Hypnotics (includes other Hypnotics)

Dermatologic Agents

·  Immunological Atopic Dermatitis

·  Steroids, Topical

Endocrine & Metabolic Agents

·  Glucocorticoids, Oral

·  Growth Hormones

·  Hereditary Angioedema (HAE)

·  Progestins for Cachexia

Gastrointestinal

·  Antiemetic/Antivertigo Agents

·  Gastrointestinal (GI) Motility, Chronic

·  H. Pylori Treatment

·  Histamine-2 Receptor Antagonists (H-2RA)

·  Proton Pump Inhibitors

·  Ulcerative Colitis (oral and rectal)

Genitourinary

·  BPH Agents (includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment)

·  Bladder Relaxants

Ophthalmics

·  Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)

·  Antibiotics

·  Antibiotic/Steroid Combinations

·  Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)

·  Glaucoma Agents (includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors)

Respiratory

·  Anti-Allergens, Oral

·  Antibiotics, Inhaled

·  Antihistamines Minimally Sedating

·  Bronchodilators, Long Acting Beta Adrenergics

·  Bronchodilators, Short Acting Beta Adrenergics

·  COPD (includes Anticholingerics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors)

·  Cough & Cold Agents (Legend)

·  Epinephrine, Self-Injected

·  Glucocorticoids (includes nebulized solutions, metered dose inhalers and combinations)

·  Intranasal Rhinitis (includes Antihistamines and Corticosteroids)

·  Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion) P&T Committee, DMAS & PS Staff Pursuant to 42 USC §1396r-8

PDL Recommendations and Vote P&T Committee Members

Criteria Discussion of Phase II New Drugs* P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes* P&T Committee Members

Next Meeting – April 21, 2017 Tim Jennings, Pharm. D., Chairman

*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.